We fund research. Our only goal is to accelerate treatment for girls and women with Rett Syndrome.
We keep our running costs to the bare bone so that the maximum percentage possible is delivered directly to the research that matters. Working in synergy with the Rett Syndrome Research Trust, RSRT UK is in prime position to drive the science forward.
With a focused and aggressive effort, Rett Syndrome may become the first reversible brain disorder.
We are doing what we can to speed the science, but we need your help.
Help us close that gap between research and treatment.
Help us ensure that high impact research avenues can be thoroughly funded and explored, bringing us closer to treatment for all of our daughters.
MECP2 Consortium Announced 07/09/11:
RSRT announces the creation of the MECP2 Consortium, a dynamic collaboration between the laboratories of three distinguished scientists, Adrian Bird, Michael Greenberg and Gail Mandel; each sharing their knowledge and expertise to better understand the function of MeCP2 protein in order to determine rational treatment pathways for our children.